The real cost of non-dilutive funding in biotech
Grants, collaborations, venture debt and royalty deals are often grouped under non-dilutive funding. Boards still have to weigh them against an equity round, and the label offers no help with that comparison.
For biotech CEOs and early-stage investors, "non-dilutive funding" is useful shorthand, but it is a poor decision framework. No new shares may be issued, yet capital carries a price in future economics, time, control, IP flexibility or strategic focus.
The better question is not, "Can we raise this without dilution?" It is: what are we giving up, when does it matter, and is that trade cheaper than equity at this stage?
"Non-dilutive" describes what happens to the cap table. It says very little about what happens to enterprise value.
The cost is merely displaced
Equity financing makes its price painfully visible. Existing holders own less of the company. That is why founders and boards naturally seek alternatives.
Grants, public contracts, pharma collaborations, royalty monetization, venture debt, tax credits and foundation funding each come with their own terms. The absence of new shares tells a board little about those terms.
In some cases the label covers a package that already includes equity. The EIC Accelerator, often filed under non-dilutive European funding, offers blended finance combining a grant of up to €2.5 million with an equity investment from the EIC Fund of between €1 million and €10 million, alongside grant-only and equity-only routes. In the round announced in June 2026, 84% of the selected companies were eligible for blended finance.1 Alacrita is an EIC Ecosystem Partner.
A grant can constrain scope. A collaboration can transfer a substantial share of future asset economics. Debt can introduce covenants and senior claims on scarce cash. A royalty deal can become expensive when a product performs better than expected.
The practical error is to compare the visible dilution of an equity round with an incomplete account of what the alternatives cost. The obligations may be familiar. Their effect on the next financing or licensing deal is easier to overlook.
There is no free capital in biotech. There is only capital with different claims on value.
Start with the public money
Government grants and contracts are often among the best financing tools available to early companies. For a program aligned with an agency's mission, they can extend runway, generate validation and fund important work that conventional investors may be unwilling to support.
In the US, the SBIR and STTR programs are an important source of funding for eligible small companies. For a preclinical company with no revenue, an award can fund work without transferring equity or asset economics. The obligations attached to it still deserve the same scrutiny a term sheet would get.
Three of those obligations are ones CEOs and VCs should price explicitly:
- Scope lock-in. Money is attached to a defined workplan, milestones and budget. Changing course may require approvals, amendments or a willingness to forgo future installments. That is manageable until the science tells you to pivot.
- Operating overhead. NIH recipients, for example, face periodic financial and progress reporting, alongside invention, utilization, audit and conflict-of-interest requirements where applicable.2,3
- IP considerations. Under Bayh-Dole, recipients may elect to retain title to federally funded inventions, subject to disclosure, patenting and other obligations, including a government license.4,5 Exclusive rights to use or sell a covered invention in the US generally require products embodying it, or made using it, to be manufactured substantially in the US, unless the agency grants a waiver.6 The detail matters when a later licensing deal or manufacturing plan depends on those rights.
Public contracts also require a separate review of data rights. The specific vehicle and agreement language determine the rights and obligations of government and contractor over data used or generated under the contract.7
None of this makes public funding unattractive. Quite the reverse. It means a company should regard a grant or BARDA-style contract as a strategic commitment, rather than merely a pleasant substitute for an equity round.
Public money also runs on a political calendar
There is a further risk that the financing comparison needs to capture. Programs such as SBIR and STTR depend on periodic reauthorization.
SBIR and STTR authority expired at the end of fiscal year 2025. In November, NIH expired its open SBIR and STTR funding opportunities and confirmed that it would not issue noncompeting continuation awards until reauthorization, although active awards could continue. The lapse ran approximately six and a half months, until the Small Business Innovation and Economic Security Act was signed on April 13, 2026, reauthorizing both programs through September 30, 2031.8,9
A company whose runway assumed a Phase II award in early 2026, or a continuation of an award already made, faced a problem that had little to do with its science or the terms of its application. Public funding has to be available when the cash is needed. Reauthorization does not itself put money in the bank.
A pharma upfront buys rights
The non-dilutive funding phrase is particularly incomplete when applied to pharma collaborations. A large-pharma upfront, cost-sharing arrangement or option deal can be rational. The right partner may provide development capability, manufacturing depth, regulatory credibility and commercial reach that a venture-backed biotech cannot sensibly replicate.
But it is not simply financing. It is the sale of a portion of an asset's future economics, accompanied by governance rights and strategic influence. The company may preserve equity ownership at the parent level while economically parting with a significant slice of its most valuable program.
For a CEO, the question should be: Would we sell these rights today if cash were not part of the conversation?
For an investor, it should be: Does this partner accelerate probability-adjusted value sufficiently to justify the economics and loss of optionality?
If the answer to either is no, the transaction may be financial engineering dressed up as strategic validation. An upfront payment can be essential to keeping a program alive, and that makes the cash valuable. It does not make the terms good.
Debt and royalties are not benign
Venture debt and royalty financing also deserve more scrutiny than the label "non-dilutive" implies. Debt can encumber IP, impose milestones or covenants, and create a senior claim on cash in precisely the scenarios where the company has least flexibility. In a downturn, that can prove more damaging than an equity raise.
Consider a company that draws a facility with a second tranche released on a Phase II readout and an interest-only period ending on a fixed date. The readout slips two quarters, which in drug development is unremarkable. The tranche does not release. Amortization begins on schedule against a smaller cash balance. The company then raises equity from a position where the lender holds a senior claim and the data are not yet in hand, a costly position from which to price a round. Nothing in that sequence required the science to fail.
A royalty monetization has a different profile. It can be an elegant tool for a later-stage company with an underwritable revenue stream. Yet the company is selling part of the upside of an asset that, if successful, is often its most valuable source of future cash flow.
Neither is inherently wrong. Both should be modeled against an equity-financed path in good, base and bad cases, not merely presented as a way to preserve percentage ownership.
From an Alacrita engagement
Asked to assess the monetization of an oncology royalty stream, we modeled product sales and future royalties under different scenarios, expressed those royalties in present values and tested the key sensitivities. That is the analysis a headline payment cannot replace. See pharmaceutical and biotech valuations.
Foundation funding can carry substantial economics
Foundation money is also filed under non-dilutive, and the economics can be substantial: in November 2014, Cystic Fibrosis Foundation Therapeutics, the Foundation's nonprofit affiliate, sold the royalty rights arising from its support of Vertex's cystic fibrosis program to Royalty Pharma for $3.3 billion.10
Depending on the agreement, venture philanthropy can carry royalties or milestones, restrictions on the funded work and continuing development commitments in the indication. A large return to the funder does not establish that equity would have been cheaper, but a board should price those terms rather than the label.
A better board discussion
The most useful discipline is to compare the financing routes actually available on the same basis: usable cash, timing, obligations and value retained. Grants and public contracts impose commitments on what the company must do, where, and for how long. Debt and royalty deals create claims on future cash. Those differences matter, and sorting these routes into dilutive and non-dilutive obscures them.
Figure 1 · What each route claims, and when the claim bites
| Financing route | What the claim is on | When it bites |
|---|---|---|
| Equity round | Ownership and control | At close, permanently |
| Grant or public contract | Conduct: scope, reporting, IP | When the science says pivot |
| Pharma collaboration | Future economics of one asset | At the next licensing deal |
| Venture debt | Cash, senior and date-certain | When a readout slips |
| Royalty monetization | A share of future royalties | If the product outperforms |
| Foundation funding | Royalties or milestones, where agreed | On success, in that indication |
Ask five questions:
- How much usable cash arrives, when, and what milestone will it fund?
- What future value, rights or flexibility are we transferring?
- What happens if the readout slips, the science fails or the program needs to change direction?
- How much value do existing shareholders retain in good, base and bad cases?
- Does delaying an equity raise take us to a stronger financing position, and can we fund the work needed to get there?
The answer may well favor a grant, a collaboration or a royalty deal. There are situations where those structures are clearly superior to equity, particularly when they fund a capability gap or materially improve the probability of success.
Equity belongs in that comparison on its actual terms too: valuation, investor rights, liquidation preferences and the time needed to close. A financing can increase the value of the business while allocating more of the proceeds to new investors, lenders or partners. The board needs to see both the value created and who retains it.
There is no free capital in biotech. There is only capital with different claims on value. The strongest CEOs and investors do not try to avoid dilution at all costs. They choose the financing that advances the program on acceptable terms and protects the long-term value retained by existing shareholders.
Frequently asked questions
Usable cash and payment dates, the work funded, obligations attached, and the consequences of delay or failure. Compare the value retained by existing shareholders across good, base and bad cases, using the terms of the equity financing or other alternatives the company could realistically secure.
Recipients may elect to retain title to federally funded inventions, subject to Bayh-Dole obligations. These include invention disclosure, patenting requirements and a government license. The US manufacturing preference can also affect an exclusive license to use or sell a covered invention in the US; an agency waiver may be available. Review those obligations before committing to a licensing or manufacturing arrangement.
Exclusivity, option rights, rights of first negotiation or refusal, consent requirements and the allocation of IP rights can narrow the next transaction. The effect depends on the agreement. A useful test is whether the company will still be able to offer a future partner the rights needed to develop and commercialize the program.
Where a facility ties later tranches to milestones but repayment begins on a fixed date, a delayed readout can leave the company repaying debt before it receives the next tranche. Model that sequence explicitly. Nothing has to go wrong scientifically for the cash position to deteriorate.
As a contingent receipt. A rare pediatric disease voucher depends on a qualifying approval, and sale proceeds depend on the price a buyer will pay. The program currently permits awards through September 30, 2029. Test the plan against a later approval, no voucher award and a lower sale price.
About the author
References
1. European Innovation Council and SMEs Executive Agency. 38 start-ups and SMEs secure EIC support in latest round of the EIC Accelerator. June 15, 2026. eic.ec.europa.eu.
2. National Institutes of Health. NIH Grants Policy Statement, Section 8.4.1: Reporting. grants.nih.gov. Accessed September 9, 2026.
3. National Institutes of Health. NIH Grants Policy Statement, Section 8.2.4: Inventions and Patents. grants.nih.gov. Accessed September 9, 2026.
4. National Institutes of Health. Intellectual Property Policy. grants.nih.gov. Accessed September 9, 2026.
5. National Institutes of Health. Bayh-Dole Act. grants.nih.gov. Accessed September 9, 2026.
6. United States Code. Title 35, Section 204: Preference for United States industry. law.cornell.edu. Accessed September 9, 2026.
7. US General Services Administration. Federal Acquisition Regulation, Part 27: Patents, Data, and Copyrights. acquisition.gov. Accessed September 9, 2026.
8. US Congress. S. 3971, Small Business Innovation and Economic Security Act, 119th Congress. congress.gov. Signed April 13, 2026. Announcement: US Small Business Administration. Administrator Loeffler Applauds SBIR-STTR Reauthorization. News release 26-43.
9. National Institutes of Health. Notice of Early Expiration of NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Notices of Funding Opportunity and Guidance for Existing Recipients. Notice NOT-OD-26-006. November 17, 2025. grants.nih.gov.
10. Royalty Pharma. Royalty Pharma Announces $3.3 Billion Royalty Transaction with Cystic Fibrosis Foundation Therapeutics. November 19, 2014. royaltypharma.com.
11. US Food and Drug Administration. Rare Pediatric Disease Designation and Priority Review Voucher Programs. Content current as of April 29, 2026. fda.gov.